[1] 朱翔,韩凌飞,杨燕,等.病毒性肝炎患者外周血T细胞亚群与病毒载量、胃蛋白酶原水平及胃黏膜病变程度的相关研究.中国免疫学杂志,2020,36(1):84-89. [2] Griebel P, Ma Q, Dong X, et al. Hepatitis B eantigen induces NKG2A(+) natural killer cell dysfunction via regulatory T cell-derived interleukin 10 in chronic hepatitis B virus infection. Hum Vaccin Immunother, 2020, 8(13): 421. [3] Kim J H, Ghosh A, Ayithan N, et al. Circulating serum HBsAg level is a biomarker for HBV-specific T and B cell responses in chronic hepatitis B patients.Sci Rep, 2020, 10(1): 1835. [4] 李铃, 敬雪明, 朱其荣, 等. 乙肝病毒感染后不同临床类型及HBV DNA载量与外周血T细胞亚群变化的相关性分析. 中国现代医学杂志, 2015,25(17):35-41. [5] 柴艳云, 李建国, 金磊. 乙型肝炎肝硬化患者外周血补体和T淋巴细胞计数的变化. 实用肝脏病杂志, 2016,19(6):724-725. [7] Abbasi A, Peeke S, Shah N, et al. Axicabta gene ciloleucel CD19 CAR-T cell therapy results in high rates of systemic and neurologic remissions in ten patients with refractory large B cell lymphoma including two with HIV and viral hepatitis. J Hematol Oncol, 2020, 13(1): 1. [8] 吕辉, 郝世勇. 乙型肝炎肝硬化患者血细胞参数的变化及意义. 临床血液学杂志:输血与检验, 2015, 28(1):115-117. [9] De Beijer M T A, Jansen D, Dou Y, et al. Discovery and selection of hepatitis B virus-derived T cell epitopes for global immunotherapy based on viral indispensability, conservation, and HLA-binding strength. J Virol, 2020, 94(7):322-325. [10] Cheng LS, Liu Y, Jiang W. Restoring homeostasis of CD4+ T cells in hepatitis B virus related liver fibrosis.World J Gastroenterol,2015,21(38): 10721-10731. [11] Whitacre D C, Peters C J, Sureau C, et al. Designing a therapeutic hepatitis B vaccine to circumvent immune tolerance. Hum Vaccin Immunother, 2020, 16(2): 251-268. [12] Wu J, Niu Q, Yuan J, et al. lncRNA-CD160 decreases the immunity of CD8(+) T cells through epigenetic mechanisms in hepatitis B virus infection. Oncol Lett, 2020, 20(1): 235-247. [13] Zawawi A, Forman R. In silico design of a T-cell epitope vaccine candidate for parasitic helminth infection. Hum Vaccin Immunother, 2020, 16(3): e1008243. |